New York has granted Sequenom approval for its noninvasive prenatal test used to detect Rhesus D incompatibility, a fetal disorder that can cause anemia and mental retardation. Sequenom's nonexclusive licensee, Lenetix Medical Screening Laboratory, will market the test, which uses SEQureDx technology to draw out fetal nucleic acid material from the mother's blood sample.

Full Story:

Related Summaries